Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

Esketamine monotherapy demonstrated beneficial antidepressant effects at multiple doses for patients with treatment-resistant depression, according to results of a phase 4 randomized trial published ...

GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a ...

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

Most existing risk assessment methods lack the capability to conduct large-scale analysis and accurately evaluate long-term trends. To solve this problem, this study integrated various methodologies, ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Estrogen plays an important role in keeping bones healthy. Now, researchers investigated how membrane-initiated estrogen receptor alpha (mERα) signaling in specific cell types of female mice affects ...

G protein-coupled receptors (GPCRs) make up the largest receptor family in humans, which also constitute principal molecular targets for about 36% of approved drugs. Recent studies show that GPCRs can ...

Elon Musk may find out what happens when DOGE bites man. The billionaire SpaceX, Tesla and X owner who catapulted his zealous embrace of President Donald Trump into a powerful position slashing ...